BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35320003)

  • 1.
    Selvanesan BC; Chandra D; Quispe-Tintaya W; Jahangir A; Patel A; Meena K; Alves Da Silva RA; Friedman M; Gabor L; Khouri O; Libutti SK; Yuan Z; Li J; Siddiqui S; Beck A; Tesfa L; Koba W; Chuy J; McAuliffe JC; Jafari R; Entenberg D; Wang Y; Condeelis J; DesMarais V; Balachandran V; Zhang X; Lin K; Gravekamp C
    Sci Transl Med; 2022 Mar; 14(637):eabc1600. PubMed ID: 35320003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for ovarian cancer is improved by tumor targeted delivery of a neoantigen surrogate.
    Scanlon LR; Gabor L; Khouri OR; Ahmad S; Levy E; Kuo DY; Lin K; Nevadunsky N; Gravekamp C
    bioRxiv; 2023 Nov; ():. PubMed ID: 37873295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.
    Selvanesan BC; Meena K; Beck A; Meheus L; Lara O; Rooman I; Gravekamp C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33154149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
    Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
    Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
    Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
    Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.
    Yang Y; Stang A; Schweickert PG; Lanman NA; Paul EN; Monia BP; Revenko AS; Palumbo JS; Mullins ES; Elzey BD; Janssen EM; Konieczny SF; Flick MJ
    Cancer Res; 2019 Jul; 79(13):3417-3430. PubMed ID: 31048498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bacterial-Based Immunotherapy for PDAC.
    Cancer Discov; 2022 Jun; 12(6):OF1. PubMed ID: 35394498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect.
    Chandra D; Selvanesan BC; Yuan Z; Libutti SK; Koba W; Beck A; Zhu K; Casadevall A; Dadachova E; Gravekamp C
    Oncotarget; 2017 Mar; 8(13):20729-20740. PubMed ID: 28186976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
    Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
    Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
    Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
    J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
    Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
    Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
    Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.